NOMATEN SEMINAR: Translational development of radiopharmaceuticals at Service Hospitalier Frédéric Joliot

Date
Date 2
Place
https://www.gotomeet.me/NCBJmeetings/nomaten-seminar

Tuesday, APRIL 19th  2022 13:00 (1.00PM CET)

Translational development of radiopharmaceuticals at Service Hospitalier Frédéric Joliot

Dr. Bertrand Kuhnast, CEA-Service Hospitalier Frédéric Joliot, Orsay, France.

 

Abstract:

The Service Hospitalier Frédéric Joliot (Orsay, France) is a translational and multimodal molecular imaging facility. It gathers on the same site two cyclotrons for the daily production of positron emitters, R&D and GMP hot labs for the manufacturing of radiotracers and radiopharmaceuticals, an experimental and preclinical imaging platform comprising PET, PET/CT, SPECT/CT scanners and ultrasound devices and finally PET/CT, PET/MRI and MRI clinical scanners. Beside the clinical nuclear medicine practice, intensive research programs are dedicated to the translational development of new radiopharmaceuticals and the support and “derisking” in drug development. During this seminar, after a rapid technical overview of our facility, I will illustrate these translational developments with two selected examples:

1/ [18F]DPA-714, a radiopharmaceutical to image neuroinflammation, from the identification of the chemical scaffold to the clinical trials: step by step development of a radiopharmaceutical.

2/ isotopic radiolabelling of dolutegravir, an antiretroviral drug, with fluorine-18 to decipher treatment limitations: hope and pitfall in the development of a complex radiosynthesis scheme and first images.

 

Bio:

Bertrand Kuhnast is head of the “Development of radiopharmaceuticals and imaging agents” within the BioMaps Unit (http://www.biomaps.universite-paris-saclay.fr/ ) located at the Service Hospitalier Frédéric Joliot (SHFJ). After an education in chemistry and a PhD dedicated to the radiolabelling and imaging of oligonucleotides, he joined the nuclear medicine Dpt of the Technical University in Munich for a two-years postdoctoral fellowship. He was recruited at the Service Hospitalier Frédéric Joliot in 2002 as radiochemist in the team of F. Dollé. From 2011 to 2014, he was responsible of the tracer and radiopharmaceutical manufacturing facility at SHFJ, then headed the Molecular Probe team within the IMIV unit and has held his current position since 2020.  The team is today composed of 5 researchers in radiochemistry, a radiopharmacist, 5 technicians, 2 postdocs and 2 PhD students.

Galeria
Attachements
Résumé présentation avril 2022 (370.07 KB)

Tags



This project has received funding from the European Union Horizon 2020 research and innovation
programme under grant agreement No 857470 and from European Regional Development Fund
via Foundation for Polish Science International Research Agenda PLUS programme grant
No MAB PLUS/2018/8.
Poland
The project is co-financed from the state budget within the framework of the undertaking of the Minister of Science and Higher Education "Support for the activities of Centers of Excellence established under Horizon 2020".

Grant: 5 143 237,70 EUR
Total value: 29 971 365,00 EUR
Date of signing the funding agreement: December 2023

The purpose of the undertaking is to support entities of the higher education and science system that have received funding from the European Union budget in the competition H2020-WIDESPREAD-2018-2020/WIDESPREAD-01-2018-2019: Teaming Phase 2. in the preparation, implementation and updating of activities, maintenance of material resources necessary for carrying out activities, acquisition and modernization of scientific and research apparatus, maintenance and development of personnel potential necessary for the implementation of activities, and dissemination of the results of scientific activities.